Evidence map›Paper›PMID 42489062›Full record

ArticleHaematologica2026

Personalized measurable residual disease assays for acute myeloid leukemia guided by whole-genome sequencing.

Niveditha Ravindra, Rasha W Al-Ali, Justin Lack, Clifton L Dalgard, Eddy VanCollenburg, Adam Corner, Lan Beppu, Harry Erba, Megan Othus, R Coleman Lindsley and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Niveditha RavindraLaboratory of Myeloid Malignancies, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Rasha W Al-AliFralin Biomedical Research Institute, Virginia Tech FBRI Cancer Research Center.
Justin LackIntegrated Data Sciences Section, National Institutes of Health, Bethesda, MD.
Clifton L DalgardThe American Genome Center, Uniformed Services University of the Health Sciences, Bethesda, MD.
Eddy VanCollenburgBio-Rad Laboratories, Digital Biology Group, 5731, W. Las Positias Blvd, Pleasanton, CA.
Adam CornerBio-Rad Laboratories, Digital Biology Group, 5731, W. Las Positias Blvd, Pleasanton, CA.
Lan BeppuTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA.
Harry ErbaDuke University School of Medicine, Durham, NC.
Megan OthusPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA.
R Coleman LindsleyDana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Jerald P RadichPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA.
Laura W DillonFralin Biomedical Research Institute, Virginia Tech FBRI Cancer Research Center. ldillon@vtc.vt.edu.
Christopher S HouriganFralin Biomedical Research Institute, Virginia Tech FBRI Cancer Research Center. hourigan@measuremrd.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Not available.

Identifiers

PMID42489062

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.